

Chapter 3D Appendix

Buprenorphine Induction and Maintenance Appropriate Use Checklists

4	
BTOD REMS	

Patient Name:			

APPROPRIATE USE CHECKLIST:

BUPRENORPHINE-CONTAINING TRANSMUCOSAL PRODUCTS FOR OPIOID DEPENDENCE

This checklist is a useful reminder of the safe use conditions and monitoring requirements for prescribing buprenorphine-containing transmucosal products for opioid dependence.

Requirements to address during each patient's appointment include:

- understanding and reinforcement of safe use conditions
- the importance of psychosocial counseling
- screening and monitoring patients to determine progress towards treatment goals

If a patient continues to abuse various drugs or is unresponsive to treatment, including psychosocial intervention, it is important that you assess the need to refer the patient to a specialist and/or a more intensive behavioral treatment environment.

Additional resource: Physician Clinical Support System: http://pcssb.org/

This checklist may be used during the induction period and filed in patient's medical record to document safe use conditions. Once a maintenance dose has been established, use the maintenance checklist.

MEASUREMENT TO ENSURE APPROPRIATE USE	NOTES
Date:	
INDUCTION	
☐ Verified patient meets appropriate diagnostic criteria for opioid dependence	
Discussed risks described in professional labeling and Medication Guide with patient	
Explained or reviewed conditions of safe storage of medication, including keeping it out of the sight and reach of children	
☐ Provided induction doses under appropriate supervision	
☐ Prescribed limited amount of medication at first visit	
Scheduled next visit at interval commensurate with patient stability Weekly, or more frequent visits recommended for the first month	,



45	Patient Name:
APPROPRIATE USE CHECKLIST:	
BTOD REMS BUPRENORPHINE-CONTAINING TRANSMUCO	SAL PRODUCTS FOR OPIOID DEPENDENCE
This checklist may be used for visits following the induction	period and filed in patient's medical record to document safe use condition
	<u> </u>
MEASUREMENT TO ENSURE APPROPRIATE USE	NOTES
Date: Visit #	
MAINTENANCE	
Assessed and encouraged patient to take	
medication as prescribed Consider pill/film count/dose reconciliation	
,	
Assessed appropriateness of dosage	
Buprenorphine combined with naloxone is recommended for maintenance:	
Buprenorphine/Naloxone SL tablet and film	
(Suboxone®): doses ranging from 12 mg to 16 mg of buprenorphine are recommended for	
maintenance	
 Buprenorphine/Naloxone SL tablet (Zubsolv®): a target dose of 11.4 mg buprenorphine is 	
recommended for maintenance	
Buprenorphine/Naloxone Buccal Film Section 100	
(Bunavail®): a target dose of 8.4 mg of buprenorphine is recommended for	
maintenance	
Doses higher than this should be an exception The need for higher dose should be carefully	
evaluated	
☐ Conduct urine drug screens as appropriate to assess use of illicit substances	
Assessed participation in professional counseling and support services	
Assessed whether benefits of treatment	
with buprenorphine-containing products outweigh risks associated with buprenorphine-	
containing products	
Assessed whether patient is making adequate progress toward treatment goals	
Considered results of urine drug screens as part	
of the evidence of the patient complying with the treatment program	
Consider referral to more intensive forms of	
treatment for patients not making progress	
Scheduled next visit at interval commensurate	
with patient stability	

Available online (<u>www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2017-01-23_Appropriate_Use_Checklist.pdf</u>). Reprinted from material in the public domain.³⁴⁴

2